This readme.txt file was generated 20250106 by Kumar, D. and edited by data curator on 20250319 Recommended citation for the data: Kumar, D., Pride, M., Mukherjee, K., Jain, G., Mutreja, I., & Jones, R. S. (2025). The use of Oxymetazoline-based Nasal Solutions to remove Bacteria-Blood Debris and Eradicate Rothia dentocariosa: an ex vivo cavity model study - Data Sharing Archive [Data set]. Data Repository for the University of Minnesota (DRUM). https://doi.org/10.13020/9KFE-W805 ------------------- GENERAL INFORMATION ------------------- 1. Title of Dataset: The use of Oxymetazoline-based Nasal Solutions to remove Bacteria-Blood Debris and Eradicate Rothia dentocariosa: an ex vivo cavity model study - Data Sharing Archive 2. Author Information: Principal Investigator Contact Information Name: Dhiraj Kumar Institution: University of Minnesota Address: Diagnostic and Biological Sciences, University of Minnesota, 515 Delaware St SE, Minneapolis 55455. Email: kumard@umn.edu ORCID: 0000-0002-1008-8638 Associate or Co-investigator Contact Information Name: Robert S Jones Institution: University of Minnesota Address: Developmental and Surgical Sciences, University of Minnesota, 515 Delaware St SE, Minneapolis 55455. Email: rsjones@umn.edu ORCID: 0000-0002-9213-3657 Associate or Co-investigator Contact Information Name: Morgan Pride Institution: North Carolina Agricultural and Technical State University [2023 Summer Research at University of Minnesota] Address: Greensboro, NC, 27411, USA. Email: decline to state; undergraduate student ORCID: N/A Associate or Co-investigator Contact Information Name: Mukherjee, Kaushik Institution: University of Minnesota Address: 515 Delaware St SE, Moos Tower, UMN Email: mukhe107@umn.edu ORCID: Associate or Co-investigator Contact Information Name: Jain, Gaurav Institution: University of Minnesota Address: 515 Delaware St SE, Moos Tower, UMN Email: jainx291@gmail.com ORCID: Associate or Co-investigator Contact Information Name: Mutreja, Isha Institution: University of Minnesota Address: 515 Delaware St SE, Moos Tower, UMN Email: "isha.mutreja@gmail.com" ORCID: 0000-0002-8998-7563 3. Date published or finalized for release: 2025-01-06 4. Date of data collection (single date, range, approximate date) 2022-03-01 to 2024-04-30 5. Geographic location of data collection (where was data collected?): Moos Tower, School of Dentistry, University of Minnesota 515 Delaware St SE, Minneapolis MN 55455. 6. Information about funding sources that supported the collection of the data: National Institutes of Health grants R01 DE027669 (Primary) and R25 DE032529 (Morgan Pride - MnCORE undergraduate) 7. Overview of the data (abstract): Background: This study evaluated the antibacterial properties of a potential pulpal medicament, a nasal solution with oxymetazoline (NS-OXY, 0.05%), against a dentinal caries pathogen. Methods: Using a disc diffusion susceptibility test (n=6), Rothia dentocariosa was grown on brain-heart infusion (BHI) agar plates and exposed to OXY (0.05%), benzalkonium chloride (BKC-0.025%), OXY-NS (with OXY-0.05% and BKC), ferric sulfate (20%; ViscoStat), and distilled water (DI). This was followed by exposure of an ex vivo dental caries model with sheep blood to simulate the clinical pulpotomy procedure. An antibacterial broth inhibition test was conducted by adding the test samples in BHI broth at 37±0.5 °C in an aerobic chamber. Results: In the disc diffusion test, NS-OXY and BKC had the largest zone of inhibition (ZOI) measuring 14.42 mm (±1.62) and 18.92 mm (±4.14) respectively, indicating antibacterial activity. Ferric sulfate demonstrated a smaller ZOI, while OXY alone had no ZOI. The antibacterial broth test showed antibacterial effects with stable OD and pH levels for test samples containing BKC (0.025%) and diluted NS-OXY (0.01%) for up to 20 h. DI- and OXY-treated samples showed an increase in OD, indicating an increase in bacterial count and a concurrent drop in pH. BKC treatment statistically (P<0.05) reduced polyP extracts, which may contribute to blood clot formation. NS-OXY demonstrated antibacterial properties, likely due to the addition of BKC to Rothia dentocariosa. NS-OXY showed concentration dependent biocompatibility with dental pulp stem cells while FS was cytotoxic at the same dilution. Conclusion: These antimicrobial properties, together with OXY’s hemostatic effects, suggest the potential off-label use of NS-OXY during a pulpotomy procedure in primary and permanent teeth. This study provides support for potential future clinical trials of repurposing FDA-approved drugs consisting of oxymetazoline and benzalkonium chloride for dental and other similar applications. Featured Application: An over-the-counter nasal solution containing oxymetazoline has the potential to be used off-label to manage surgical bleeding from dental pulp exposures and provide antimicrobial properties against Rothia dentocariosa, a model gram-positive bacteria associated with deep dentinal caries. -------------------------- SHARING/ACCESS INFORMATION -------------------------- 1. Licenses/restrictions placed on the data: Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ 2. Links to publications that cite or use the data: submitted 3. Was data derived from another source? No 4. Terms of Use: Data Repository for the U of Minnesota (DRUM) By using these files, users agree to the Terms of Use. https://conservancy.umn.edu/pages/policies/#drum-terms-of-use --------------------- DATA & FILE OVERVIEW --------------------- 1. File List A. Filename: Figure_1B_Zone of inhibition Short description: Zone of inhibition graph data for compounds NS-OXY (0.05%, Stock, BKC (0.025%), OXY (0.05%), and VS-Ferric sulfate (20%, Stock). B. Filename: Figure_2A_OD-pH_Control Short description: Rothia dentocariosa growth in media without any treatment as a measurement of optical density (OD) and measured pH value. C. Filename: Figure_2B_OD-pH_NS-OXY Short description: Rothia dentocariosa growth in media with NS-OXY (0.01%, 1:5 Dilution) treatment as a measurement of optical density (OD) and measured pH value. D. Filename: Figure_2C_OD-pH_BKC Short description: Rothia dentocariosa growth in media with BKC (0.025%) treatment as a measurement of optical density (OD) and measured pH value. E. Filename: Figure_2D_OD-pH_OXY Short description: Rothia dentocariosa growth in media with OXY (0.05%) treatment as a measurement of optical density (OD) and measured pH value. F. Filename: Figure_3A_change in PO4 draw Short description: Quantification of inorganic phosphate drawn from media for each treatment. G. Filename: Figure_3B_change in PolyP Short description: Quantification of polyphosphate (polyP) as inorganic phosphate synthesized by Rd and isolated using natural phenol assay for each treatment. H. Filename: Figure_4B_Crystal violet assay Short description: Quantification of Rothia dentocariosa biomass in the prepped and treated/washed cavity using respective reagent using crystal violet assay. I. Filename: Figure_5_Metabolic activity Short description: Metabolic activity or biocompatibility of hDPSCs after treatment with respective reagent and allowed to recover for 24h after treatment, quantified using alamarBlue assay. 2. Relationship between files: Each file contains data to support manuscript figures. -------------------------- METHODOLOGICAL INFORMATION -------------------------- 1. Description of methods used for collection/generation of data: 1. Anti-bacterial assessment using Discs inhibition and growth inhibition absorbance assays, 2. biomass quantification in an ex vivo cavity model using crystal violet assay, 3. inorganic phosphate uptake and polyp quantification using colorimetric ascorbic acid assay, 4. Metabolic activity or biocompatibility of active and non-active reagents with human Dental Pulp Stem cells using alamarBlue colorimetric assay. 2. Methods for processing the data: Statistical Analysis using GraphPad Prism software. 3. Instrument- or software-specific information needed to interpret the data: 4. Standards and calibration information, if appropriate: 5. Environmental/experimental conditions: 6. Describe any quality-assurance procedures performed on the data: 7. People involved with sample collection, processing, analysis and/or submission: